The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Letter to the editor

Reply: Applicability of ISCHEMIA in real-world practice: where to START?

EuroIntervention 2021;17:e183-e184. DOI: 10.4244/EIJ-D-21-00018R

1. Division of Cardiology, A.O. San Camillo-Forlanini, Rome, Italy; 2. Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
We thank Meier and colleagues1 for their valuable comments on our manuscript assessing the external applicability of the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial2 in a cohort of 5,070 consecutive patients with stable coronary artery disease (SCAD) enrolled in the START (STable Coronary Artery Diseases RegisTry) registry3. First of all, they questioned why we also included in our analysis patients with a recent episode of acute coronary syndrome (ACS). In the 2013 European Society of Cardiology (ESC) guidelines, the definition of SCAD also included the stabilised, often asymptomatic, phases that immediately follow an ACS episode4. ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Optimal Dual Antiplatelet Therapy Duration for Bioresorbable Scaffolds: an Individual Patient Data Pooled Analysis of the ABSORB Trials